Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The double blind part of the study is being conducted to compare the efficacy and safety of
pazopanib in combination with lapatinib with that of lapatinib alone in subjects with
inflammatory breast cancer whose tumors overexpress the ErbB2 protein. There is also an
Open-label pazopanib arm to this study designed to test whether pazopanib given alone and
lapatinib given alone would be safe and effective to treat patients with inflammatory breast
cancer.